×
About 8,975 results

ALLMedicine™ Leukemias Center

Research & Reviews  2,319 results

Phase I Trial of Turalio(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform ...
https://clinicaltrials.gov/ct2/show/NCT02390752

Feb 3rd, 2023 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Feb 3rd, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

Clinical Profile and Outcome of 806 Pediatric Oncology Patients Treated With Radiothera...
https://doi.org/10.1097/MPH.0000000000002589
Journal of Pediatric Hematology/oncology; Bokun J, Popović-Vuković M et. al.

Feb 3rd, 2023 - Radiotherapy plays an important role in the multimodal treatment of childhood cancer. Our objective was to provide an analysis of pediatric oncology patients treated with radiotherapy in a national referral institution in Serbia. A retrospective c...

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885707
Molecular Cancer; Maalej KM, Merhi M et. al.

Feb 1st, 2023 - In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, tha...

Hodgkin Lymphoma in Children and Adolescents of Northern Greece: 25-Year Results and Lo...
https://doi.org/10.1097/MPH.0000000000002625
Journal of Pediatric Hematology/oncology; Kourti M, Papakonstantinou E et. al.

Jan 31st, 2023 - Aim of this study was to evaluate the long-term therapeutic outcome and treatment-related complications in Hodgkin disease. We reviewed the medical records of 93 patients diagnosed with classic Hodgkin lymphoma, treated, and followed-up during the...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  422 results see all →

Clinicaltrials.gov  237 results

Phase I Trial of Turalio(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform ...
https://clinicaltrials.gov/ct2/show/NCT02390752

Feb 3rd, 2023 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Feb 3rd, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lym...
https://clinicaltrials.gov/ct2/show/NCT04726241

Jan 31st, 2023 - PRIMARY OBJECTIVES: I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials. II. To maintain a longitudinal and comprehensive r...

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03289910

Jan 30th, 2023 - PRIMARY OBJECTIVE: I. To estimate and compare the complete response/complete response with incomplete recovery (CR/CRi) rate of induction therapy with topotecan hydrochloride (topotecan)/carboplatin (T/C) with or without veliparib (V) in myeloprol...

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
https://clinicaltrials.gov/ct2/show/NCT05521087

Jan 30th, 2023 - The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring ...

see more →

News  605 results

Mastocytosis: Rare, underdiagnosed, potentially fatal
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD

Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll

Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...

Treatments for MCL Continue to Progress
https://www.onclive.com/view/treatments-for-mcl-continue-to-progress

Nov 18th, 2022 - As research and treatment options for patients with mantle cell lymphoma (MCL) continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step...

CAR Therapy Era Moves Forward With Much Excitement, Lingering Questions
https://www.onclive.com/view/car-therapy-era-moves-forward-with-much-excitement-lingering-questions

Nov 16th, 2022 - CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017. From a clinical standpoint, these therapies have significantly improved outcomes in disease settings where the outlook for ...

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction
https://www.onclive.com/view/innovations-are-poised-to-lead-mpn-mds-treatment-landscape-in-a-positive-direction

Nov 9th, 2022 - A full day of programming on hematologic malignancies will kick off the 40th Annual Chemotherapy Foundation Symposium. Included in the lineup highlighting advances in multiple myeloma, leukemias, lymphomas, and other issues across malignancies, a ...

see more →

Patient Education  5 results see all →